Use of botulinum toxin in the neurology clinic

Nature Reviews Neurology

Volumn 6, Issue 11, 2010, Pages 624-636

  Lim, Erle C H ^a   Seet, Raymond C S ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BUPIVACAINE; CLONIDINE; DOPAMINE RECEPTOR BLOCKING AGENT; ETIRACETAM; GABAPENTIN; GUANFACINE; LIDOCAINE; NEURONOX; PRIMIDONE; SCOPOLAMINE; TETRABENAZINE; TOPIRAMATE; UNCLASSIFIED DRUG; ZONISAMIDE;

ARTHRALGIA; AUTONOMIC DYSFUNCTION; BEHAVIOR THERAPY; BLEPHAROSPASM; BRAIN DEPTH STIMULATION; CERVICAL DYSTONIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; ECHOGRAPHY; ELECTROMYOGRAPHY; ENDOSCOPY; ESSENTIAL TREMOR; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; FACE PAIN; FOCAL DYSTONIA; HAND TREMOR; HEADACHE; HEALTH CARE NEED; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; LOW BACK PAIN; MIGRAINE; NERVE COMPRESSION; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; PATIENT ATTITUDE; PELVIS PAIN SYNDROME; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; SEGMENTAL DYSTONIA; SINGLE DRUG DOSE; SPASMODIC DYSPHONIA; SPASTICITY; TIC; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE;

BOTULINUM TOXINS; DECISION TREES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; ELECTROMYOGRAPHY; GUIDELINE ADHERENCE; HUMANS; INJECTIONS, INTRAMUSCULAR; NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES;

EID: 78149411107     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.149     Document Type: Review

References (138)

1. Schulte-Mattler, w. J. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs 22, 725-738 (2008).
2. Erbguth, F. J. & Naumann, M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology 53, 1850-1853 (1999).
3. van Ermengem, E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as "Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus" in Zeitschrift für Hygiene und Infektionskrankheiten. 26, 1-56, 1897. Rev. Infect. Dis. 1, 701-719 (1979).
4. Scott, A. B., Rosenbaum, A. & Collins, C. C. Pharmacologic weakening of extraocular muscles. Invest. Ophthalmol. 12, 924-927 (1973).
5. Scott, A. B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J. Pediatr. Ophthalmol. Strabismus 17, 21-25 (1980).
6. Kerner, J. Das Fettgift oder die Fettsaure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur untersuchung des in verdorbenen Wursten giftig wirkenden Stoffes (Stuttgart, Tubingen: Cotta; 1822).
7. Lim, E. C. & Seet, R. C. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurol. Scand. 117, 73-84 (2008).
8. Esquenazi, A. Botulinum neurotoxin in muscle overactivity. J. Head Trauma Rehabil. 20, 563-567 (2005).
9. Aoki, K., Smith, L. A. & Atassi, M. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit. Rev. Immunol. 30, 167-187 (2010).
10. Kukreja, R. et al. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon 53, 616-624 (2009).
11. Oguma, K. et al. Structure and function of clostridium botulinum progenitor toxin. J. Toxicol. Toxin Rev. 18, 17-34 (1999).
12. Poulain, B., Popoff, M. & Molgó, J. How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J. 1, 14-87 (2008).
13. Panjwani, N., O'Keefe, R. & Pickett, A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J. 1, 153-166 (2008).
14. Dressler, D. Pharmacological aspects of therapeutic botulinum toxin preparations [German]. Nervenarzt. 77, 912-921 (2006).
15. Pickett, A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon 54, 683-689 (2009).
16. Arezzo, J. C. NeuroBloc/Myobloc: unique features and findings. Toxicon 54, 690-696 (2009).
17. Simpson, L. L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44, 167-193 (2004).
18. Black, J. D. & Dolly, J. O. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J. Cell Biol. 103, 521-534 (1986).
19. Jankovic, J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 75, 951-957 (2004).
20. Jabbari, B. Botulinum neurotoxins in the treatment of refractory pain. Nat. Clin. Pract. Neurol. 4, 676-685 (2008).
21. Pickett, A. Re-engineering clostridial neurotoxins for the treatment of chronic pain: current status and future prospects. BioDrugs 24, 173-182 (2010).
22. Jankovic, J. & Fahn, S. Dystonic disorders. In Parkinson's Disease And Movement Disorders (eds Jankovic, J. & Tolosa, E.) 321-347 (williams and wilkins, Baltimore, 1993).
23. Albanese, A. et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur. J. Neurol. 13, 433-444 (2006).
24. Rosenkranz, K. et al. Sensorimotor reorganization by proprioceptive training in musician's dystonia and writer's cramp. Neurology 70, 304-315 (2008).
25. Nelson, A. J., Blake, D. T. & Chen, R. Digitspecific aberrations in the primary somatosensory cortex in writer's cramp. Ann. Neurol. 66, 146-154 (2009).
26. Brashear, A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics 3, 1-7 (2009).
27. Dashtipour, K. & Pender, R. A. Evidence for the effectiveness of botulinum toxin for writer's cramp. J. Neural Transm. 115, 653-656 (2008).
28. Kenney, C. & Jankovic, J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J. Neural Transm. 115, 585-591 (2008). (Pubitemid 351534034)
29. Bhidayasiri, R., Cardoso, F. & Truong, D. D. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur. J. Neurol. 13 (Suppl. 1), 21-29 (2006).
30. Simpson, D. M. et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1699-1706 (2008).
31. Jankovic, J. Treatment of dystonia. Lancet Neurol. 5, 864-872 (2006).
32. Turjanski, N. et al. Botulinum toxin in the treatment of writer's cramp. Clin. Neuropharmacol. 19, 314-320 (1996).
33. Dressler, D. Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur. J. Neurol. 7, 713-718 (2000).
34. Tey, H. L. & Lim, E. C. Neurology. In The Black Book Of Clinical Examination (eds Tey, H. L. & Lim, E. C.) 54-150 (McGraw-Hill, Singapore, 2009).
35. Singer, C., Papapetropoulos, S. & vela, L. Use of mirror dystonia as guidance for injection of botulinum toxin in writing dysfunction. J. Neurol. Neurosurg. Psychiatry 76, 1608-1609 (2005).
36. Hallett, M. et al. Treatment of focal dystonias with botulinum neurotoxin. Toxicon 54, 628-633 (2009).
37. Adam, O. R. & Jankovic, J. Treatment of dystonia. Parkinsonism Relat. Disord. 13 (Suppl. 3), S362-S368 (2007).
38. Ivanhoe, C. B. & Reistetter, T. A. Spasticity: the misunderstood part of the upper motor neuron syndrome. Am. J. Phys. Med. Rehabil. 83 (10 Suppl.), S3-S9 (2004).
39. Esquenazi, A. et al. Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon 54, 634-638 (2009).
40. Esquenazi, A. & Mayer, N. Botulinum toxin for the management of muscle overactivity and spasticity after stroke. Curr. Atheroscler. Rep. 3, 295-298 (2001).
41. Simpson, D. M. et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1691-1698 (2008).
42. Lim, E. C., Ong, B. K. & Seet, R. C. Botulinum toxin-A injections for spastic toe clawing. Parkinsonism Relat. Disord. 12, 43-47 (2006).
43. Lim, E. C., Quek, A. M. & Seet, R. C. Botulinum toxin-A injections via electrical motor point stimulation to treat writer's cramp: pilot study. Neurol. Neurophysiol. Neurosci. 4, 1-7 (2006).
44. Keenan, M. A. et al. Management of intrinsic spasticity in the hand with phenol injection or neurectomy of the motor branch of the ulnar nerve. J. Hand Surg. Am. 12, 734-739 (1987).
45. Shaw, L. & Rodgers, H. Botulinum toxin type A for upper limb spasticity after stroke. Expert Rev. Neurother. 9, 1713-1725 (2009).
46. Hoare, B. J. et al. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database of Systematic Reviews Issue 1, Art. No.: CD003469. doi:10.1002/14651858.CD003469.pub4(2010).
47. Lukban, M. B., Rosales, R. L. & Dressler, D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. J. Neural Transm. 116, 319-331 (2009).
48. Francisco, G. E. Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice. Ann. Acad. Med. Singapore 36, 22-30 (2007).
49. Turner-Stokes, L. et al. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomized clinical trial. J. Rehabil. Med. 42, 81-89 (2010).
50. Delgado, M. R. et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 74, 336-343 (2010).
51. Chang, C. L. et al. Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy. Arch. Phys. Med. Rehabil. 90, 1462-1468 (2009).
52. Gracies, J. M., Singer, B. J. & Dunne, J. w. The role of botulinum toxin injections in the management of muscle overactivity of the lower limb. Disabil. Rehabil. 29, 1789-1805 (2007).
53. Brin, M. F. et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov. Disord. 2, 237-254 (1987).
54. Binder, w. J. et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol. Head Neck Surg. 123, 669-676 (2000).
55. Mahowald, M. L., Singh, J. A. & Dykstra, D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox. Res. 9, 179-188 (2006).
56. Piovesan, E. J. et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 65, 1306-1308 (2005).
57. Qerama, E. et al. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 67, 241-245 (2006).
58. winner, P. Botulinum toxins in the treatment of migraine and tension-type headaches. Phys. Med. Rehabil. Clin. N. Am. 14, 885-899 (2003).
59. Naumann, M. et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1707-1714 (2008). (Pubitemid 351644139)
60. Harden, R. N. et al. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache 49, 732-743 (2009).
61. Burstein, R., Dodick, D. & Silberstein, S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon 54, 624-627 (2009).
62. Kim, C. C. et al. Predicting migraine responsiveness to botulinum toxin type A injections. Arch. Dermatol. 146, 159-163 (2010).
63. Jakubowski, M. et al. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 125, 286-295 (2006).
64. Qerama, E., Fuglsang-Frederiksen, A. & Jensen, T. S. The role of botulinum toxin in management of pain: an evidence-based review. Curr. Opin. Anaesthesiol. 23, 602-610 (2010).
65. Yang, S. S., Seet, R. C. & Lim, E. C. Actioninduced hemifacial spasm and its resolution with botulinum toxin. Mov. Disord. 24, 147-148 (2009).
66. Frei, K., Truong, D. D. & Dressler, D. Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations. Eur. J. Neurol. 13 (Suppl. 1), 30-35 (2006).
67. Bentsianov, B. & Blitzer, A. Facial anatomy. Clin. Dermatol. 22, 3-13 (2004).
68. Borodic, G. E., Cheney, M. & McKenna, M. Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast. Reconstr. Surg. 90, 972-977 (1992).
69. Ondo, w. G. Essential tremor: treatment options. Curr. Treat. Options Neurol. 8, 256-267 (2006).
70. Shprecher, D. & Kurlan, R. The management of tics. Mov. Disord. 24, 15-24 (2009).
71. Blaheta, H. J. et al. Intravenous regional anesthesia (Bier's block) for botulinum toxin therapy of palmar hyperhidrosis is safe and effective. Dermatol. Surg. 28, 666-671 (2002).
72. Haider, A. & Solish, N. Focal hyperhidrosis: diagnosis and management. CMAJ 172, 69-75 (2005).
73. Stolman, L. P. Treatment of hyperhidrosis. J. Drugs Dermatol. 2, 521-527 (2003).
74. Grunfeld, A., Murray, C. A. & Solish, N. Botulinum toxin for hyperhidrosis: a review. Am. J. Clin. Dermatol. 10, 87-102 (2009).
75. Lowe, N. J. et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J. Am. Acad. Dermatol. 56, 604-611 (2007).
76. weber, A. et al. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. Br. J. Dermatol. 152, 342-345 (2005).
77. Kontochristopoulos, G., Gregoriou, S., Zakopoulou, N. & Rigopoulos, D. Cryoanalgesia with dichlorotetrafluoroethane spray versus ice packs in patients treated with botulinum toxin-a for palmar hyperhidrosis: self-controlled study. Dermatol. Surg. 32, 873-874 (2006).
78. Richards, R. N. Ethyl chloride spray for sensory relief for botulinum toxin injections of the hands and feet. J. Cutan. Med. Surg. 13, 253-256 (2009).
79. Smith, K. C., Comite, S. L. & Storwick, G. S. Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis. Dermatol. Surg. 33, S88-S91 (2007).
80. Lim, E. C. & Seet, R. C. Another injection-free method to effect analgesia when injecting botulinum toxin for palmar hyperhidrosis: cryoanalgesia. Dermatol. Online J. 13, 25 (2007).
81. Merello, M. Sialorrhoea and drooling in patients with Parkinson's disease: epidemiology and management. Drugs Aging 25, 1007-1019 (2008).
82. Scully, C., Limeres, J., Gleeson, M., Tomás, I. & Diz, P. Drooling. J. Oral Pathol. Med. 38, 321-327 (2009).
83. Brin, M. F. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 6, S208-S220 (1997).
84. Moore, P. & Naumann, M. Muscles and recommended dose ranges of botulinum toxins for adults. In Handbook of Botulinum Toxin Treatment (eds Moore, P. & Naumann, M.) 438-453 (Blackwell, Cornwall, 2005).
85. Brin, M. F., Danisi, F. & Blitzer, A. Blepharospasm, oromandibular dystonia, Meige's syndrome and hemifacial spasm. In Handbook of Botulinum Toxin Treatment (eds Moore, P. & Naumann, M.) 119-141 (Blackwell Science, Oxford, 2003).
86. Rosales, R. L., Bigalke, H. & Dressler, D. Pharmacology of botulinum toxin: differences between type A preparations. Eur. J. Neurol. 13 (Suppl. 1), 2-10 (2006).
87. wohlfarth, K., Kampe, K. & Bigalke, H. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov. Disord. 19 (Suppl. 8), S65-S67 (2004).
88. Dressler, D. Botulinum toxin for treatment of dystonia. Eur. J. Neurol. 17 (Suppl. 1), 88-96 (2010).
89. Coté, T. R., Mohan, A. K., Polder, J. A., walton, M. K. & Braun, M. M. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J. Am. Acad. Dermatol. 53, 407-415 (2005).
90. O'Flaherty, S. & waugh, M. C. Pharmacologic management of the spastic and dystonic upper limb in children with cerebral palsy. Hand Clin. 19, 585-589 (2003).
91. Gracies, J. M., Nance, P., Elovic, E., McGuire, J. & Simpson, D. M. Traditional pharmacological treatments for spasticity. Part II: general and regional treatments. Muscle Nerve Suppl. 6, S92-S120 (1997). (Pubitemid 128753040)
92. Esquenazi, A., Mayer, N. H., Elia, A. E. & Albanese, A. Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon 54, 634-638 (2009).
93. Sakzewski, L., Ziviani, J. & Boyd, R. Systematic review and meta-analysis of therapeutic management of upper-limb dysfunction in children with congenital hemiplegia. Pediatrics 123, e1111-e1122 (2009).
94. Hexsel, D., Rutowitsch, M. S., de Castro, L. C., do Prado, D. Z. & Lima, M. M. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol. Surg. 35, 933-939 (2009).
95. Carruthers, A. & Carruthers, J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin. Cutan. Med. Surg. 20, 71-84 (2001).
96. Trindade De Almeida, A. R. Kadunc, B. v., Di Chiacchio, N. & Neto, D. R. Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol. Surg. 29, 530-531 (2003).
97. Redaelli, A. & Forte, R. Botulinum toxin dilution: our technique. J. Cosmet. Laser Ther. 5, 218-219 (2003).
98. vadoud-Seyedi, J. & Simonart, T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br. J. Dermatol. 156, 986-989 (2007).
99. Li, M., Goldberger, B. A. & Hopkins, C. Fatal case of BOTOX-related anaphylaxis? J. Forensic Sci. 50, 169-172 (2005).
100. Perouansky, M. Liaisons dangereuses? General anesthetics and long-term toxicity in the CNS. Eur. J. Anaesthesiol. 24, 107-115 (2007).
101. Brée, B., Gourdin, M. & De Kock, M. Anesthesia and cerebral apoptosis. Acta Anaesthesiol. Belg. 59, 127-137 (2008).
102. Haller, I. et al. Neurotoxicity of lidocaine involves specific activation of the p38 mitogenactivated protein kinase, but not extracellular signal regulated or c-jun N-terminal kinases, and is mediated by arachidonic acid metabolites. Anesthesiology 105, 1024-1033 (2006).
103. Callaway, J. E., Arezzo, J. C. & Grethlein, A. J. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin. Cutan. Med. Surg. 20, 127-136 (2001).
104. Setler, P. The biochemistry of botulinum toxin type B. Neurology 55 (Suppl. 5), S22-S28 (2000).
105. Perotto, A. O. et al. in Anatomical Guide for the Electromyographer: the Limbs and Trunk (ed. Perotto, A. O.) 6-292 (Charles C. Thomas, Springfield, IL, 2005).
106. Mejia, N. I., vuong, K. D. & Jankovic, J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov. Disord. 20, 592-597 (2005).
107. Greene, P., Fahn, S. & Diamond, B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord. 9, 213-217 (1994).
108. Jankovic, J., vuong, K. D. & Ahsan, J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60, 1186-1188 (2003).
109. Hanna, P. A. & Jankovic, J. Mouse bioassay versus western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50, 1624-1629 (1998).
110. Jankovic, J. et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67, 2233-2235 (2006).
111. de Oliveira Monteiro, E. Botulinum toxin and pregnancy. Skinmed 5, 308 (2006).
112. Morgan, J. C. Iyer, S. S., Moser, E. T., Singer, C. & Sethi, K. D. Botulinum toxin A during pregnancy: a survey of treating physicians. J. Neurol. Neurosurg. Psychiatry 77, 117-119 (2006).
113. Fasano, A., Bentivoglio, A. R., Ialongo, T., Soleti, F. & Evoli, A. Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology 64, 2155-2156 (2005).
114. Molgó, J., Lemeignan, M. & Thesleff, S. Aminoglycosides and 3, 4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve 10, 464-470 (1987).
115. Santos, J. I., Swensen, P. & Glasgow, L. A. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 68, 50-54 (1981).
116. Smith, A. G. Pearls and pitfalls in the therapeutic use of botulinum toxin. Semin. Neurol. 24, 165-174 (2004).
117. O'Brien, C. F. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve Suppl. 6, S176-S180 (1997).
118. Lim, A. Y. et al. Intramuscular innervation of upper-limb skeletal muscles. Muscle Nerve 29, 523-530 (2004).
119. Bickerton, L. E., Agur, A. M. & Ashby, P. Flexor digitorum superficialis: locations of individual muscle bellies for botulinum toxin injections. Muscle Nerve 20, 1041-1043 (1997).
120. wang, L., Li, Y. M. & Li, L. Meta-analysis of randomized and controlled treatment trials for achalasia. Dig. Dis. Sci. 54, 2303-2311 (2009).
121. Doodnath, R. & Puri, P. Internal anal sphincter achalasia. Semin. Pediatr. Surg. 18, 246-248 (2009).
122. Kinney, T. P., Shah, A. G., Rogers, B. H. & Ehrenpreis, E. D. Retrograde endoscopic delivery of botulinum toxin for anal fissures. Endoscopy 38, 654 (2006).
123. Bistritz, L. & Bain, v. G. Sphincter of Oddi dysfunction: managing the patient with chronic biliary pain. World J. Gastroenterol. 12, 3793-3802 (2006).
124. DasGupta, R. & Murphy, F. L. Botulinum toxin in paediatric urology: a systematic literature review. Pediatr. Surg. Int. 25, 19-23 (2009).
125. Rhew, K., Fiedler, D. A. & Ludlow, C. L. Technique for injection of botulinum toxin through a flexible nasolaryngoscope. Otolaryngol. Head Neck Surg. 111, 787-794 (1994).
126. Ford, C. N., Bless, D. M. & Lowery, J. D. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia. Otolaryngol. Head Neck Surg. 103, 752-758 (1990).
127. Chuang, Y. C. & Chancellor, M. B. The application of botulinum toxin in the prostate. J. Urol. 176, 2375-2382 (2006).
128. wilken, B., Aslami, B. & Backes, H. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 39, 200-204 (2008).
129. Berweck, S., Schroeder, A. S., Fietzek, U. M. & Heinen, F. Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet 363, 249-250 (2004).
130. Berweck, S. & Heinen, F. in Treatment of Cerebral Palsy with Botulinum Toxin A - Principles, Clinical Practice, Atlas (eds Berweck, S. et al.) 1-142 (Child & Brain, Bonn, Berlin, 2003).
131. Berweck, S. & wissel, J. Sonographic imaging for guiding botulinum toxin injections in limb muscles. Adv. Clin. Neurosci. Rehab. 4, 28-31 (2004).
132. Shaari, C. M., George, E., wu, B. L., Biller, H. F. & Sanders, I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 101, 960-964 (1991).
133. Carli, L., Montecucco, C. & Rossetto, O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 40, 374-380 (2009).
134. Goodman, G. Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis. Dermatol. Surg. 29, 533-538 (2003).
135. Brisinda, G. et al. Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery 131, 179-184 (2002).
136. Francisco, G. E. Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice. Ann. Acad. Med. Singapore 36, 22-30 (2007).
137. Karp, B. I. Botulinum toxin treatment of occupational and focal hand dystonia. Mov. Disord. 19 (Suppl. 8), S116-S119 (2004).
138. Edlund, w. et al. American Academy of Neurology Clinical Practice Guideline Process Manual [online], http://www.aan.com/professionals/practice/ pdfs/2004-Guideline-Process.pdf(2004).